Common drugs prescribed to treat heartburn, ulcers, and acid reflux are associated with an increased risk for developing chronic kidney disease and kidney failure.
People taking common heartburn drugs are at a higher risk for developing chronic kidney disease and kidney failure, reports a new study. The findings of the study are published in the journal Pharmacotherapy. Common medications //prescribed to treat heartburn, acid reflux and ulcers are linked to increased risks for kidney failure and chronic kidney disease, found a recent University at Buffalo study.
‘Common medications prescribed to treat heartburn, ulcers, and acid reflux may increase the risk of developing chronic kidney disease and kidney failure.’
Read More..
Use of proton pump inhibitors (PPI), a group of drugs that reduce the production of stomach acid, increases the risk of chronic kidney disease by 20 percent and raises the risk of kidney failure by four times. Risks were highest among people at least 65 years old.Read More..
The research is one of the first large, long-term studies to examine the effects of PPIs on kidney function. Researchers examined the health data of more than 190,000 patients over a 15-year period.
"This study adds to a growing list of concerning side effects and adverse outcomes associated with PPIs," says David Jacobs, PharmD, Ph.D., lead investigator and assistant professor of pharmacy practice in the UB School of Pharmacy and Pharmaceutical Sciences.
"Given the increasing global use of PPIs, the relationship between PPIs and renal disease could pose a substantial disease and financial burden to the health care system and public health."
PPIs are one of the most commonly prescribed medications in the U.S., with an estimated 113 million prescriptions filled in 2008, costing patients nearly $14 billion, says Jacobs.
Advertisement
The prevalence of PPI use in the U.S. could have a devastating effect on public health. Because these drugs are still considered safe, education and deprescribing initiatives are needed to raise awareness among health care providers, says Jacobs. Deprescribing may involve reducing dosage or stopping usage.
Advertisement
Kidney health was compared between patients who underwent PPI therapy and those who were unexposed. Examined PPIs included esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole (commonly known by brand names as Vimovo, Prevacid, Prilosec, Protonix and Aciphex, respectively).
Source-Eurekalert